U.S. stocks edge higher after weekly jobless claims; Salesforce gains
WILMINGTON, Del. - AstraZeneca (AZN), a prominent player in the pharmaceuticals industry with a market capitalization of $281.42 billion, will present data from its hematology portfolio and pipeline at the upcoming 67th American Society of Hematology (ASH) Annual Meeting and Exposition on December 6-9, 2025, featuring 65 abstracts across eight approved and investigational medicines.
The company will share initial data from two investigational therapies: surovatamig, a CD19xCD3 T-cell engager being studied in relapsed/refractory follicular lymphoma, and AZD0120, a BCMAxCD19 chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma. These pipeline developments are crucial for AstraZeneca, which has seen strong revenue growth of 13.52% over the last twelve months, reaching $58.13 billion.
Key presentations will include three-year follow-up results from a first-in-human trial of surovatamig in follicular lymphoma and initial data from the DURGA-1 Phase Ib/II study of AZD0120 in multiple myeloma.
The company will also present 50-month follow-up data from the ECHO Phase III trial evaluating CALQUENCE plus bendamustine and rituximab in first-line mantle cell lymphoma, and additional results from a Phase III trial of ULTOMIRIS in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy.
"We are advancing a broad pipeline of investigational therapies with the potential to redefine patient care across multiple types of blood cancer," said Anas Younes, Senior Vice President, Hematology R&D and Chief Medical Officer at AstraZeneca, in a press release statement.
The company will also present data on CALQUENCE in chronic lymphocytic leukemia, VOYDEYA as an add-on to ULTOMIRIS or SOLIRIS in paroxysmal nocturnal hemoglobinuria, and real-world evidence highlighting the impact of ULTOMIRIS across approved indications.
This year’s ASH congress will feature AstraZeneca’s largest presence to date, with 15 oral presentations among the 65 abstracts being presented.
In other recent news, AstraZeneca has announced several significant developments. The U.S. Food and Drug Administration (FDA) has granted Priority Review status to AstraZeneca’s New Drug Application for baxdrostat, a treatment for hard-to-control hypertension in adults. The FDA is expected to make a decision by the second quarter of 2026. Additionally, AstraZeneca’s IMFINZI, in combination with FLOT chemotherapy, has received FDA approval for treating early-stage gastric and gastroesophageal junction cancers. The approval is based on results from the Phase III MATTERHORN trial, which showed a notable reduction in the risk of disease progression and death.
Furthermore, AstraZeneca disclosed that it issued 67,907 ordinary shares under its employee share plans over a recent six-month period. On the financial analysis front, Morgan Stanley raised its price target for AstraZeneca to GBP155.00, maintaining an Overweight rating. The investment bank highlighted AstraZeneca’s potential for sector-leading earnings growth and a promising pipeline. These recent developments highlight AstraZeneca’s ongoing progress in both regulatory approvals and financial performance projections.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.